Danaher Corporation (DHR) Guidance & Earnings Results

On 2026-10-21 Danaher Corporation raised guidance: "FY2026 adjusted diluted EPS raised to $8.57-$8.62 from $8.45-$8.60; Q4 2026 core revenue ex-respiratory growth 4.0%-5.0% YoY; respiratory headwind ~150bps; core revenue growth…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-09-25 · read by EquiReason

DHRDanaher CorporationFollow DHR — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 162.2B
P/E TTM: 37.7
Dividend yield: 0.6%
52-week: —
Next earnings: 26 Jan, in 94 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
21 Oct 26	Raised	FY2026 adjusted diluted EPS raised to $8.57-$8.62 from $8.45-$8.60; Q4 2026 core revenue ex-respiratory growth 4.0%-5.0% YoY; respiratory headwind ~150bps; core revenue growth ~3.0% · full year
21 Jul 26	Raised	Full-year 2026 adjusted EPS guidance raised to $8.45-$8.60 from $8.35-$8.55 · full year
21 Apr 26	Raised	Adjusted EPS guidance raised by $0.05 at midpoint · full year
28 Jan 26	Raised	FY2026 core revenue growth 3-6%; adjusted EPS $8.35-$8.50 · full year
12 Jan 26	Raised	Q4 core revenue toward high-end of low-single digit guidance; adjusted EPS toward high-end of $7.70-$7.80 · full year
21 Oct 25	Reaffirmed	FY2025 adjusted diluted EPS $7.70-$7.80; non-GAAP core revenue growth low-single digits YoY · full year

Danaher Corporation — questions

What guidance did Danaher Corporation give?: On 2026-10-21: "FY2026 adjusted diluted EPS raised to $8.57-$8.62 from $8.45-$8.60; Q4 2026 core revenue ex-respiratory growth 4.0%-5.0% YoY; respiratory headwind ~150bps; core revenue growth ~3.0%"
When does Danaher Corporation report earnings?: Danaher Corporation's next earnings report is expected on 2027-01-26.

Every figure on this page comes from Danaher Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.